DRUG · Mapped RxNorm record
Abemaciclib
Normalized identity: abemaciclibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
NCT04352777
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Fulvestrant
Normalized identity: fulvestrantView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
Aromatase Inhibitors
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedImpact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Metastatic Breast Cancerunresolved
Locally Advanced Breast Cancerunresolved
Hormone Receptor Positive Tumorunresolved
Interventions
AbemaciclibDRUG · verified · RxNorm: abemaciclib
FulvestrantDRUG · verified · RxNorm: fulvestrant
Sponsors & collaborators
Duke Universitylead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04352777 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.